Dublin, Ireland-based Shire Pharmaceuticals has issued a voluntary recall on three lots of VPRIV, a long-term intravenous enzyme replacement therapy for patients with type 1 Gaucher disease, due to stainless steel and barium sulfate particulate matter found in a few vials.
Shire believes the patient risk to be very low, but serious adverse events associated with the barium sulfate particulate could occur, though none have been reported yet, according to a news release.
More Articles on Recalls:
Pfizer Recalls 3 Lots of Effexor XR, Generic Equivalent
GE Healthcare Recalls Infant Resuscitation Systems
Philips Respironics Recalls Trilogy Ventilators Worldwide